Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Genesis announced that it has completed its second successful human transplant with a genetically engineered pig kidney, with ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...

Relying on a single strand of hair, LinusBio is launching its diagnostic aid for autism spectrum disorder—with a test ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

Kura and Kyowa used the announcement to confirm that they are on track to file a new drug approval application with the FDA ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...